286 related articles for article (PubMed ID: 12607727)
1. Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
Kneitz C; Wilhelm M; Tony HP
Immunobiology; 2002 Dec; 206(5):519-27. PubMed ID: 12607727
[TBL] [Abstract][Full Text] [Related]
2. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
[TBL] [Abstract][Full Text] [Related]
4. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
5. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
6. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.
Faurschou M; Hasselbalch HC; Nielsen OJ
Eur J Haematol; 2001 Jun; 66(6):408-11. PubMed ID: 11488941
[TBL] [Abstract][Full Text] [Related]
7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
8. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
9. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
Eisenberg R
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
[TBL] [Abstract][Full Text] [Related]
10. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
11. SLE - Rituximab in lupus.
Eisenberg R
Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
[TBL] [Abstract][Full Text] [Related]
12. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
13. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
[TBL] [Abstract][Full Text] [Related]
14. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
15. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab for treatment of patients with systemic autoimmune diseases].
García Hernández FJ; Ocaña Medina C; González León R; Garrido Rasco R; Colorado Bonilla R; Castillo Palma MJ; Sánchez Román J
Med Clin (Barc); 2007 Mar; 128(12):458-62. PubMed ID: 17408540
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus.
Lee SY; Hsu PY; Juan KC; Chang H; Huang WH; Lai PC
Int Immunopharmacol; 2010 May; 10(5):632-4. PubMed ID: 20172055
[TBL] [Abstract][Full Text] [Related]
18. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Marks SD; Tullus K
Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
[TBL] [Abstract][Full Text] [Related]
19. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
20. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]